

TRANSMITTAL

COPY OF PAPERS ORIGINALLY FILED

type a plus symmetries box TM + Approved for use through 10/31/02. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number. 10/017,327

Application Number

IRANSIVIIIIAI	Filing Date	December 6, 20	RECEIVED	
FORM		First Named Inventor	Charles A. NIC	
		Group Art Unit	1645	AUG 2 1 2002
(to be used for all correspondence after in	nitial filing)	Examiner Name	Not Yet Assign	TECH CENTER 1690/2900
Total Number Of Pages In This Submission	7	Attorney Docket No.	GZ 2101.20	ILON OLIVILIT 1000/2500
	ENCLOS	URES (check all that	apply)	
Fee Transmittal Form		signment Papers		After Allowance Communication to Group
Fee Attached		wing(s)		Appeal Communication to Board of Appeals and Interferences
Amendment / Reply	Lice	ensing-related Papers		Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)
After Final	Pet	ition		Proprietary Information
Affidavits/declarations		ition to Convert to a		Status Letter
Extension of Time Request		wer of Attorney, Revocation ange of Correspondence Ad	dress	Other Enclosure(s) (please identify below): postcard receipt
	Ter	minal Disclaimer		posical direction
Express Abandonment Request	Red	quest for Refund		
Supplemental Information Disclosure Statement w/ PTO 1449A & PTO 1449B	CD	, Number of CD(s)		
Certified Copy of Priority Document(s) Remarks			
Response to Missing Parts/ Incomplete Application				
Response to Missing Parts under 37 CFR 1.52 or 1.53				
SIGNA	TURE OF	APPLICANT, ATTORN	IEY OR AGE	ENT
Firm Antoinette F. Kons Bingham McCutch Or Three Enbarcade Individual Name San Francisto, CA	en LLP (formerly	y McCutchen Doyle Brown & Ene 1800	ersen LLP)	
Signature Milwu		myll		
Date MG.	13° Z	002		
	C	ERTIFICATE OF MAILING		
I hereby certify that this correspondence is the an envelope addressed to: Commissioner for Dated: Aug. 13	peing deposite or Patents, W	ashington, D.C. 20231, on U	stel Service with	n sufficient postage as first class mail in elow:
1		Mary R. Zimmemian		-

Burden Hours Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Box Patent Application, Washington, DC 20231.

PATENT Docket No. GZ 2101.20 GZ Ref. 5028 USP1

CERTIFICATE OF MAILING

I hereby certify that this paper or fee is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 2011 on this date listed below.

RECEIVED AUG 2 1 2002 TECH CENTER 1600/29 IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application for:

Charles A. NICOLETTE

Serial No.: 10/017,327

Filing Date: December 6, 2001

For: COMPOUNDS FOR THERAPY AND

DIAGNOSIS AND METHODS FOR

USING SAME

Examiner: Not Yet Assigned

Group Art Unit: 1645

COPY OF PAPERS ORIGINALLY FILED

Commissioner for Patents Washington, D.C. 20231

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

In accordance with 37 C.F.R. § 1.56, the references listed on the attached forms PTO-1449a and PTO-1449b are being brought to the attention of the Examiner for consideration in connection with the examination of the above-identified patent application. The Examiner is requested to make these documents of record.

I. Timing of the Information Disclosure Statement:

This Information Disclosure Statement is filed:

With the new patent application submitted herewith (37 C.F.R. § 1.97(a)).
Within three months after the filing date of the application or within three months after the date of entry of the national stage of a PCT application as set
forth in 37 C.F.R. § 1.491.

	Before the mailing date of a first Office action on the merits. In the event, however, that an Office Action has crossed in the mail with this Information Disclosure Statement, the Commissioner is hereby authorized to charge Deposit Account No. 50-1189 for any fees required pursuant to 37 C.F.R. §§ 1.17(p) or 1.17(i)(1).
This Informat	tion Disclosure Statement is filed:
	After the first Office Action and more than three months after the application's filing date; or PCT national stage date of entry filing but, as far as is known to the undersigned, prior to the mailing date of either a final rejection or a notice of allowance, whichever occurs first, and the Commissioner is hereby authorized to charge Deposit Account No.[] for the fee (\$180) set forth in 37 C.F.R. § 1.17(p) and any additional required fees.
This Informat	tion Disclosure Statement is filed:
	After the mailing date of either a final rejection or a notice of allowance, whichever occurred first, and is accompanied by the fee (\$180.00) set forth in 37 C.F.R. § 1.17(i)(1) and a certification as specified in 37 C.F.R. § 1.97(e), as checked below. This document is to be considered as a petition requesting consideration of the Information Disclosure Statement.
The undersign	ned certifies that:
	Each item of information contained in the Information Disclosure Statement was first cited in any communication mailed from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this information disclosure statement.
	No item of information contained in this information disclosure statement was cited in a communication mailed from a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned after making reasonable inquiry, was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing of this Information Disclosure Statement.
II. Copies of	f the Cited Items:
	Copies of all of the items listed on the attached Form PTO-1449 are enclosed.
	Copies of only the following items listed on the attached Form PTO-1449 are enclosed:
	Copies of the items listed in the attached Form PTO-1499 are not supplied because they were previously cited by or submitted to the Patent Office in a prior Application No. 09/870,216 filed May 30, 2001 and relied upon in this

2

Serial No.: 10/017,327 Docket No.: GZ 2101.20 GZ Ref.: 5028 USP1

		application for an earlier filing date under 35 U.S.C § 120. See 37 C.F.R. § 1.98(d).
		Copies of those items which are marked with an asterisk (**) in the attached Form PTO-1499 were cited in a foreign examination report in a related case. A copy of the search report and the cited references not already of record in this application are attached hereto.
ш.	Concise	Explanation of Relevance:
	\boxtimes	A concise explanation of relevance of the items listed on Form PTO-1449 is not given.
		A concise explanation of relevance of [some of] the items listed on Form PTO-1449 is in the form of an English language copy of a Search Report from a foreign patent office, issued in a counterpart application, which refers to the relevant portions of the references (copy attached).
IV.	Related	l Applications:
		Applicants bring to the Office's attention the following related, co-pending application(s):
v.	Conclus	sion:
Cita	tion of th	e above documents shall not be construed as:
	,1.	an admission that the documents are necessarily prior art with respect to the

- a representation that a search has been made, other than as described above; or 2.
- an admission that the information cited herein is, or is considered to be, material to patentability as defined in $\S 1.56(b)$. 3.

It is respectfully requested that the Examiner indicate consideration of the cited references by returning a copy of the attached form PTO 1449 with initials or other appropriate marks. The Commissioner is hereby authorized to charge Deposit Account No. 50-1189, billing reference number: 19442-7247 for any additional fees required in connection with the filing of this Information Disclosure Statement.

Respectfully submitted,

Dated: Mug. 13, 2002

Antoinette F. Konsk

Registration No. 34,202

Bingham McCutchen LLP (formerly McCutchen Doyle Brown & Enersen LLP)

Three Embarcadero Center, Suite 1800 San Francisco, California 94111-4067

Telephone: (650) 849-4950 Facsimile: (650) 849-4800

PTO/SB/08A (10-01) hrough 10/31/2002. OMB 0651-0031

+

U.S. Patent and Trademark Office. U.S. DEPARTMENT OF COMMERCE
Under the aperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

TRACE NOTE FOR TOWN 1449A-PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 1

Complete if Known		
Application Number	10/017,327	
Filing Date	December 6, 2001	
First Named Inventor	Charles A NICOLETTE	
Art Unit	1645	
Examiner Name	Not Yet Assigned	
Attorney Docket Number	GZ 2101.20	

U.S. PATENT DOCUMENTS					
Examiner	Cite	Document Number	Publication Date	Name of Patentee or	Pages, Columns, Lines,
Initials*	No.1	Number – Kind Code ² (if known)	MM-DD-YY	Application of Cited Document	Where Relevant Passages or Relevant Figures Appear
		US-			
		US-			
		US-			DECEWED
		US-			HEULIVIL
		US-			
		US-			AUG 2 1 2002
		US-			
		US-			TECH CENTER 1600/290
		US-			TECH OF MEN 199
		US-			
<u> </u>		US-			

Examiner	Cite	Foreign Patent Document	Publication Date	Name of Patentee or	Pages, Columns, Lines,	
Initials*	No. ¹	Country Code ³ – Number ⁴ – Kind Code ⁵ (if known)	MM-DD-YY	Application of Cited Document	Where Relevant Passages or Relevant Figures Appear	Т
	1	WO 97/34613	09-25-97	University of Virginia		
	2	WO 00/20457 A	04-13-00	Genzyme Corp.		
	3	WO 01/92294 A	12-06-01	Genzyme Corp.		
	4	WO 01/92306 A	12-06-01	Genzyme Corp.		-
				·		
						-
			 		 	\vdash

Examiner's	Date	
Signature	Considered	

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to compete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

COPY OF PAPERS ORIGINALLY FILED

^{*} EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08B (10-01)

Approved for a parough 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

TRADEMA			Complete if Known		
ubstitute for form 144	9В-РТО			Application Number	10/017,327
INEOE	MATION F	ماددا مو	IIDE	Filing Date	December 6, 2001
INFORMATION DISCLOSURE			-	First Named Inventor	Charles A. NICOLETTE
STATEMENT BY APPLICANT		ANI	Art Unit	1645	
(us	e as many sheets	as necessary)	Examiner Name	Not Yet Assigned
Shoot		of	4	Attornov Docket Number	G7 2101 20

	 -	OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal,
initials-	1	serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher city and/or country where published ASANO, K. et al. "Structure of cDNAs encoding human eukaryotic initiation factor 3 subunits" <i>J. Biol. Chem.</i> (October 24, 1997) 272(43):27042-27052
	2	NUPPONEN, N.N. et al. "Amplification and overexpression of p40 subunit of eukaryotic translation initiation factor 3 in breast and prostate cancer" <i>Am. J. Path.</i> (June, 1999) 154(6) :1777-1783
	3	RAMAKRISHNA, V. et al. "Generation and phenotypic characterization of new human ovarian cancer cell lines with the identification of antigens potentially recognizable by HLA-restricted cytotoxic T cells" Int'l J. Cancer (September 26, 1997) 73(1):143-150
	4	DENTON, G. et al. "Induction of antibody responses to breast cancinoma associated mucins using synthetic peptide constructs as immunogens" <i>Cancer Lets.</i> (July 16, 1993) 70(3) :143-150
		DECEIVED
		RECEIVED AUG 2 1 2002
		AUG 2 1 2002 TECH CENTER 1600/25
· • • • • • • • • • • • • • • • • • • •		
Examiner's Signature		Date Considered

COPY OF PAPERS ORIGINALLY FILED

^{*} EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to compete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.